Eledon Pharmaceuticals (ELDN) 10-Q 4 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Jul. 31, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Trading Symbol	TKAI
Entity Registrant Name	TOKAI PHARMACEUTICALS INC
Entity Central Index Key	1,404,281
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		22,634,825

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 12,156	$ 24,023
Marketable securities	31,771	39,934
Prepaid expenses and other current assets	2,259	3,213
Total current assets	46,186	67,170
Property and equipment, net	401	489
Restricted cash	270	270
Other assets		45
Total assets	46,857	67,974
Current liabilities:
Accounts payable	1,846	1,208
Accrued expenses	5,971	4,954
Total current liabilities	7,817	6,162
Long-term liabilities	156	88
Total liabilities	7,973	6,250
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 200,000,000 shares authorized; 22,634,825 and 22,597,144 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively	23	23
Additional paid-in capital	195,245	193,194
Accumulated other comprehensive income (loss)	6	(55)
Accumulated deficit	(156,390)	(131,438)
Total stockholders' equity	38,884	61,724
Total liabilities and stockholders' equity	$ 46,857	$ 67,974

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	22,634,825	22,597,144
Common stock, shares outstanding	22,634,825	22,597,144

Statements of Operations and Co

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	9,895	5,855	17,826	16,414
General and administrative	3,680	3,127	7,229	5,868
Total operating expenses	13,575	8,982	25,055	22,282
Loss from operations	(13,575)	(8,982)	(25,055)	(22,282)
Interest income and other income, net	49	25	103	65
Net loss	$ (13,526)	$ (8,957)	$ (24,952)	$ (22,217)
Net loss per share, basic and diluted	$ (0.60)	$ (0.40)	$ (1.10)	$ (0.99)
Weighted average common shares outstanding, basic and diluted	22,634,825	22,421,622	22,629,917	22,403,031
Comprehensive loss:
Net loss	$ (13,526)	$ (8,957)	$ (24,952)	$ (22,217)
Other comprehensive income:
Unrealized gains (losses) on marketable securities	11	(2)	61	(2)
Total other comprehensive income (loss)	11	(2)	61	(2)
Total comprehensive loss	$ (13,515)	$ (8,959)	$ (24,891)	$ (22,219)

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net loss	$ (24,952)	$ (22,217)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	2,014	1,240
Depreciation expense	105	21
Release of reserve for loan to former advisor		(49)
Premium on purchase of marketable securities	(2)	(35)
Amortization of premium on marketable securities	76	1
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	999	(1,307)
Accounts payable	638	905
Accrued expenses	1,017	(636)
Other assets		(45)
Other long-term liabilities	68	13
Net cash used in operating activities	(20,037)	(22,109)
Cash flows from investing activities:
Proceeds from maturities of marketable securities	8,650
Purchases of marketable securities	(500)	(24,078)
Purchases of property and equipment	(17)	(192)
Change in restricted cash		(70)
Net cash provided by (used in) investing activities	8,133	(24,340)
Cash flows from financing activities:
Repayment of notes receivable		49
Proceeds from exercise of common stock options	37	228
Net cash provided by financing activities	37	277
Net decrease in cash and cash equivalents	(11,867)	(46,172)
Cash and cash equivalents at beginning of period	24,023	105,256
Cash and cash equivalents at end of period	$ 12,156	59,084
Supplemental disclosure of non-cash investing activities:
Purchases of property and equipment included in accounts payable and accrued expenses		$ 135

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Nature of the Business and Basis of Presentation	1. Nature of the Business and Basis of Presentation Tokai Pharmaceuticals, Inc. (the “Company”) was incorporated on March 26, 2004 under the laws of the State of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company’s lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of current second-generation androgen signaling inhibitors, while also introducing a distinct third mechanism – androgen receptor degradation. The Company is developing galeterone for the treatment of patients with metastatic castration resistant prostate cancer (“CRPC”). As further described in the Note 8, Subsequent Events, on July 26, 2016, the Company announced plans to discontinue ARMOR3-SV, its pivotal Phase 3 clinical trial of galeterone, following the recommendation made by the trial’s independent data monitoring committee. The Company plans to analyze the totality of the unblinded study data to evaluate potential paths forward for galeterone and the Company’s pipeline. Based on preliminary data reviewed to date, however, there is a substantial likelihood that the Company will not pursue the development of galeterone in AR-V7 positive CRPC in the future. On July 29, 2016, the Company announced a reduction of approximately 60% of its workforce. Since its inception, the Company has devoted substantially all of its efforts to research and development, in-licensing technology and raising capital. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Galeterone, which is currently under development, and any product candidates that the Company may seek to develop in the future, will require significant additional research and development efforts, including extensive preclinical and clinical testing, formulation development and manufacturing, and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance capabilities. There can be no assurance that the Company’s research and development activities will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that any products developed will obtain necessary regulatory approval or that any approved products will be commercially viable. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and contracted service providers. The Company’s financial statements have been prepared on the basis of continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business. The Company has incurred losses and negative cash flows from operations since inception. As of June 30, 2016, the Company had an accumulated deficit of $156,390 and had cash and investments of $43,927. The Company is evaluating the sufficiency of its cash and investments to fund operations in light of the discontinuation of the ARMOR3-SV trial and reduction in workforce that were announced in July 2016. The Company is currently evaluating potential paths forward for galeterone and its pipeline, but expects its cash and investments balance to be sufficient to fund operations into at least the first half of 2017. The Company will need to obtain substantial additional funding in order to complete the development of, and to commercialize, galeterone for patients with CRPC, submit a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for galeterone, conduct other ongoing and planned clinical trials of galeterone, and develop or commercialize any future product candidates. If the Company is unable to raise capital when needed or on acceptable terms, it may be forced to delay, reduce, terminate or eliminate its product development programs and commercialization efforts. The Company’s ability to generate product revenue and operating cash flow will depend heavily on the successful development and eventual commercialization of galeterone and other product candidates that it may develop in the future. The balance sheet at December 31, 2015 was derived from audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“GAAP”). The accompanying unaudited financial statements as of June 30, 2016 and for the three and six months ended June 30, 2016 and 2015 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The Company believes, however, that the disclosures are adequate to make the information presented not misleading. These financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K that was filed with the SEC on March 10, 2016. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s financial position as of June 30, 2016 and results of operations for the three and six months ended June 30, 2016 and 2015 and cash flows for the six months ended June 30, 2016 and 2015 have been made. The results of operations for the three and six months ended June 30, 2016 and 2015 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2016.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates, assumptions and judgments reflected in these financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates. Marketable Securities The Company’s marketable securities are classified as available-for-sale and are carried at fair value with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains and losses and declines in value judged to be other than temporary are included as a component of interest income and other income, net based on the specific identification method. The Company classifies its marketable securities with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities are available for current operations. At June 30, 2016, marketable securities by security type consisted of: Gross Gross Estimated Amortized Unrealized Unrealized Fair Cost Gains Losses Value Certificates of Deposit (due within one year) $ 9,980 $ — $ — $ 9,980 United States Treasury Notes (due within one year) 21,785 6 — 21,791 Total $ 31,765 $ 6 $ — $ 31,771 At December 31, 2015, marketable securities by security type consisted of: Gross Gross Estimated Amortized Unrealized Unrealized Fair Cost Gains Losses Value Certificates of Deposit (due within one year) $ 13,709 $ — $ — $ 13,709 Certificates of Deposit (due after one year through two years) 1,178 — — 1,178 United States Treasury Notes (due within one year) 22,596 — (47 ) 22,549 United States Treasury Notes (due after one year through two years) 2,506 — (8 ) 2,498 Total $ 39,989 $ — $ (55 ) $ 39,934 Fair Value Measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The following tables present the Company’s fair value hierarchy for its cash equivalents and marketable securities, which are measured at fair value on a recurring basis at June 30, 2016 and December 31, 2015: Fair Value Measurements at June 30, 2016 Using Level 1 Level 2 Level 3 Total Cash equivalents: Money Market Instruments $ — $ 10,039 $ — $ 10,039 Marketable securities: Certificates of Deposit — 9,980 — 9,980 United States Treasury Notes — 21,791 — 21,791 Total $ — $ 41,810 $ — $ 41,810 Fair Value Measurements at December 31, 2015 Using Level 1 Level 2 Level 3 Total Cash equivalents: Money Market Instruments $ — $ 18,361 $ — $ 18,361 Marketable securities: Certificates of Deposit — 14,887 — 14,887 United States Treasury Notes — 25,047 — 25,047 Total $ — $ 58,295 $ — $ 58,295 The carrying values of accounts payable and accrued expenses approximate their fair value due to the short-term nature of these liabilities. Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period. Because the inclusion of common share equivalents in the calculation would be anti-dilutive for all periods presented, diluted net loss per share is the same as basic net loss per share. The following common share equivalents outstanding as of June 30, 2016 and 2015 were excluded from the computation of diluted net loss per share for the three and six months ended June 30, 2016 and 2015 because they had an anti-dilutive impact: June 30, December 31, 2016 2015 Stock options to purchase common stock 2,911,215 2,861,011 Unvested restricted common stock units 34,128 40,953 2,945,343 2,901,964 Recently Issued Accounting Pronouncements In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2014-15, Presentation of Financial Statements — Going Concern Subtopic 205-40). In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Accrued Expenses	3. Accrued Expenses Accrued expenses consisted of the following: June 30, 2016 December 31, 2015 Accrued research and development expenses $ 4,506 $ 3,188 Accrued payroll and related expenses 934 900 Accrued professional fees 468 699 Accrued other 63 167 $ 5,971 $ 4,954

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	4. Income Taxes The Company did not provide for any income taxes in the six months ended June 30, 2016 or 2015. The Company had gross deferred tax assets of $51,028 at December 31, 2015, which increased by approximately $10,000 at June 30, 2016. The Company has provided a valuation allowance for the full amount of its net deferred tax assets because, at each of June 30, 2016 and December 31, 2015, it was more likely than not that any future benefit from deductible temporary differences and net operating loss and tax credit carryforwards would not be realized. The Company has not recorded any amounts for unrecognized tax benefits as of June 30, 2016 or December 31, 2015. As of June 30, 2016 and December 31, 2015, the Company had no accrued interest or tax penalties recorded. The Company’s income tax return reporting periods since December 31, 2012 are open to income tax audit examination by the federal and state tax authorities. In addition, because the Company has net operating loss carryforwards, the Internal Revenue Service is permitted to audit earlier years and propose adjustments up to the amount of net operating losses generated in those years.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	5. Stock-Based Compensation The Company grants stock-based awards under its 2014 Stock Incentive Plan and is authorized to issue, but has not issued as of June 30, 2016, common stock under its 2014 Employee Stock Purchase Plan. The Company also has outstanding stock options under its 2007 Stock Incentive Plan, but is no longer granting awards under this plan. As of June 30, 2016, 1,978,979 shares of common stock were available for issuance under the 2014 Stock Incentive Plan. As of June 30, 2016, 225,000 shares of common stock were available for issuance to participating employees under the 2014 Employee Stock Purchase Plan. The Company recorded stock-based compensation expense related to stock options and restricted common stock units in the following expense categories of its statements of operations: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Research and development $ 194 $ 140 $ 405 $ 308 General and administrative 798 466 1,609 932 $ 992 $ 606 $ 2,014 $ 1,240

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Leases In February 2015, the Company entered into a sublease with a Massachusetts limited liability company (the “Sublandlord”) for 15,981 square feet of office space in Boston, Massachusetts. The sublease is subject and subordinate to a prime lease between the Sublandlord and the prime landlord. The term of the sublease commenced on April 1, 2015 and expires on December 31, 2016. If the term of the prime lease is terminated for any reason prior to the expiration or earlier termination of the sublease, the sublease will terminate immediately and the Company will have no recourse against the Sublandlord for such termination. In June 2015, the Company entered into a lease (the “New Lease”) for the existing space with the prime landlord (the “Landlord”), which effectively extends the term until July 31, 2018. Payment escalations specified in the lease agreements are accrued such that rent expense per square foot is recognized on a straight-line basis over the terms of occupancy. Prior to April 2015, the Company leased office space in Cambridge, Massachusetts, and obtained certain office-related services on a month-to-month basis under a 30-day cancelable operating service agreement. The Company recorded exit costs of $133 in connection with the termination of the Cambridge lease, which are included in rent expense during the six months ended June 30, 2015. During the three months ended June 30, 2016 and 2015, the Company recognized $174 and $181, respectively, of rental expense related to office space. During the six months ended June 30, 2016 and 2015, the Company recognized $347 and $487, respectively, of rental expense related to office space. As of June 30, 2016, future minimum lease payments under noncancelable office leases were as follows: Remainder of 2016 $ 280 2017 839 2018 489 $ 1,608 Restricted Cash and Letters of Credit The Company held a money market account of $200 to collateralize a credit card account with its bank, which was classified as restricted cash on the balance sheet as of June 30, 2016 and December 31, 2015. The Company is required to maintain a letter of credit totaling $70 for the benefit of the Landlord of the New Lease. The Landlord can draw against the letter of credit in the event of default by the Company. The Company held $70 in a money market account to collateralize the letter of credit, which amount was also included in restricted cash on the balance sheet as of June 30, 2016 and December 31, 2015. Intellectual Property Licenses The Company has a master license agreement with the University of Maryland, Baltimore (“UMB”). Pursuant to the license agreement, UMB granted an exclusive, worldwide license, with the right to sublicense, under certain patents and patent applications to make, have made, use, sell, offer to sell and import certain anti-androgen steroids, including galeterone, for the prevention, diagnosis, treatment or control of any human or animal disease. In addition, UMB granted the Company a first option to receive an exclusive license to UMB’s rights in certain improvements to the licensed products. The Company has exercised its option and acquired exclusive rights to licensed improvements under four amendments to the license agreement. The Company is obligated to pay UMB an annual maintenance fee of $10 each year until the first commercial sale of a product developed using the licensed technology. The Company is also obligated to make milestone payments of an additional $50 for the filing of each additional investigational new drug application filed for a licensed product, aggregate milestone payments of up to $150 associated with the development of a licensed product for a particular non-prostate disease indication, and a $100 milestone payment upon the approval by the FDA of each NDA for a licensed product. There were no milestones achieved during the six months ended June 30, 2016 or 2015. The Company must also pay UMB a low-single digit percentage royalty on aggregate worldwide net sales of licensed products, including sales by sublicensees, on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last-to-expire applicable licensed patent or ten years after first commercial sale of the applicable licensed product, in each case in the applicable country. The royalty obligations are subject to specified reductions in the event that additional licenses need to be obtained from third parties or in the event of specified competition from third-party products licensed by UMB. Minimum annual royalty payments to UMB are $50 beginning in the year following the year in which the first commercial sale occurs. The Company must also pay UMB 10% of all non-royalty sublicense income received from sublicensees. Finally, the Company is responsible for all patent expenses related to the prosecution and maintenance of the licensed patents. As of June 30, 2016 the Company has not yet developed a commercial product using the licensed technologies, nor has it entered into any sublicense agreements for the technologies. In January 2015, the Company entered into an exclusive license agreement with The Johns Hopkins University (“Johns Hopkins”) pursuant to which Johns Hopkins granted the Company an exclusive, worldwide license under certain patents and patent applications, and a non-exclusive license under certain know-how, in each case with the right to sublicense, to make, have made, use, sell, offer to sell and import certain assays to identify androgen receptor variants for use as a companion diagnostic with galeterone. In addition, Johns Hopkins granted the Company an option to negotiate an exclusive license to Johns Hopkins’s rights in certain improvements to the licensed intellectual property. In consideration for the rights granted to the Company under the license agreement, the Company made an upfront payment to Johns Hopkins of $75 following the execution of the license agreement, which was recognized as research and development expense during the six months ended June 30, 2015. The Company is obligated to pay Johns Hopkins an annual minimum royalty of up to $30 and to make milestone payments to Johns Hopkins upon the achievement of specified technical and commercial milestones. If all such milestones were achieved, the total milestone payments owed to Johns Hopkins would equal $700 in the aggregate. During the year ended December 31, 2015, the Company expensed $50 related to the achievement of two of these milestones. The Company has not achieved any other milestones and, therefore, no additional liabilities for such milestone payments have been recorded in the Company’s financial statements. The Company must also pay Johns Hopkins single digit percentage royalties on aggregate worldwide net sales of licensed products (but not galeterone), including sales by sublicensees, on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last-to-expire applicable licensed patent or ten years after first commercial sale of the applicable licensed product, in each case in the applicable country. These royalty obligations are subject to specified reductions in the event that additional licenses from third parties are required. The Company must also pay Johns Hopkins 20% of all non-royalty sublicense income received from sublicensees and reimburse Johns Hopkins for patent costs. As of June 30, 2016, the Company has not yet developed a commercial product using the licensed technologies. Companion Diagnostic Development Agreement In March 2015, the Company entered into a project work plan with Qiagen Manchester Limited (“Qiagen”) under a Master Collaboration Agreement, dated January 12, 2015, between the Company and Qiagen (together with the project work plan, the “CDx Agreement”). Pursuant to the CDx Agreement, Qiagen has agreed to develop and commercialize a companion diagnostic test for use with galeterone to identify mCRPC patients with the AR-V7 splice variant. Qiagen has also developed under the CDx Agreement a clinical trial assay that was used in the Company’s pivotal Phase 3 clinical trial of galeterone in order to identify mCRPC patients whose tumor cells express AR-V7, and that may be used in future clinical trials of galeterone. Subject to the terms of the CDx Agreement, the Company paid Qiagen a fee for the exclusive right to have the circulating tumor cell enrichment technology used in the development of the companion diagnostic test, which was recognized as research and development expense during the six months ended June 30, 2015. The Company also pays Qiagen fees for the development of the AR-V7 clinical trial assay and is obligated to pay a contingent milestone payment of $1,000 upon Qiagen obtaining pre-market approval of the companion diagnostic test. Furthermore, the Company will reimburse Qiagen for certain direct out-of-pocket costs incurred by Qiagen, including for sample material. These amounts are subject to adjustment if the parties determine that changes in the scope of the development program are required. Following commercialization, the Company will have no further payment obligations to Qiagen under the Agreement. The Company will not, however, receive any revenues from future sales, if any, of the companion diagnostic test. Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with each of its directors and executive officers, which provide, among other things, that the Company will indemnify such directors and executive officers to the fullest extent permitted by law for claims arising in his or her capacity as a director or officer. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of the indemnification agreements described above. In addition, the Company maintains directors and officers insurance coverage. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its financial statements as of June 30, 2016.

401(k) Plan

401(k) Plan	6 Months Ended
	Jun. 30, 2016
Postemployment Benefits [Abstract]
401(k) Plan	7. 401(k) Plan The Company has a 401(k) plan available for participating employees who meet certain eligibility requirements. Eligible employees may defer a portion of their salary as defined by the plan. Company contributions to the plan may be made at the discretion of the Board of Directors. Since January 1, 2016, the Company has made matching contributions for the plan year ending December 31, 2016 at a rate of 100% of each employee’s contribution up to a maximum matching contribution of 3% of the employee’s eligible plan compensation and at a rate of 50% of each employee’s contribution in excess of 3% up to a maximum of 5% of the employee’s eligible plan compensation. For the six months ended June 30, 2016, the Company made matching contributions of $91 for the plan year ending December 31, 2016.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	8. Subsequent Events On July 26, 2016, the Company announced its plan to discontinue the ARMOR3-SV clinical trial following the recommendation made by the trial’s independent data monitoring committee (“DMC”) on July 25, 2016. Based on a review of all available safety and efficacy data, the DMC determined that the ARMOR3-SV trial would likely not succeed in meeting its primary endpoint of demonstrating an improvement in radiographic progression-free survival for galeterone versus enzalutamide in men with AR-V7 positive metastatic CRPC. In making its recommendation, the DMC did not cite any safety concerns with galeterone in the trial. The Company plans to analyze the totality of the unblinded study data in detail to evaluate potential paths forward for galeterone and the Company’s pipeline. Based on preliminary data reviewed to date, however, there is a substantial likelihood the the Company will not persue the development of galeterone in AR-V7 positive CRPC in the future. The Company also intends to evaluate its ongoing ARMOR2 expansion in mCRPC patients with acquired resistance to enzalutamide, and its planned study in patients who rapidly progress on either enzalutamide or abiraterone acetate. The Company will allow all patients currently enrolled in the ARMOR2 and ARMOR3-SV trials to continue on therapy following consultation with their physicians and study investigators. On July 29, 2016, in connection with the discontinuation of ARMOR3-SV, the Company announced plans to reduce its workforce by approximately 60% and expects to incur a charge of approximately $1,300 related to severance, benefits and related costs, substantially all of which will be recorded in the third quarter of 2016. On August 1, 2016, a purported stockholder of the Company filed a putative class action lawsuit in the U.S. District Court for the Southern District of New York against the Company, Jodie P. Morrison and Lee H. Kalowski, entitled Vaibhav Doshi v. Tokai Pharmaceuticals, Inc., Jodie Pope Morrison and Lee H. Kalowski, No. 1:16-cv-06106. The lawsuit alleges violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder by making allegedly false and misleading statements and omissions about the Company’s clinical trials for its drug candidate, galeterone. The lawsuit seeks, among other things, unspecified compensatory damages in connection with the Company’s allegedly inflated stock price between June 24, 2015 and July 25, 2016 as a result of those allegedly false and misleading statements, as well as interest, attorneys’ fees and costs. The Company believes it has valid defenses, and intends to engage in a vigorous defense of the litigation. However, the Company is unable to predict the ultimate outcome of this action, and, therefore cannot estimate possible losses or ranges of losses, if any, or the materiality thereof. An unexpected unfavorable resolution of this matter in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.

Summary of Significant Accoun14

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates, assumptions and judgments reflected in these financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.
Marketable Securities	Marketable Securities The Company’s marketable securities are classified as available-for-sale and are carried at fair value with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains and losses and declines in value judged to be other than temporary are included as a component of interest income and other income, net based on the specific identification method. The Company classifies its marketable securities with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities are available for current operations.
Fair Value Measurements	Fair Value Measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The following tables present the Company’s fair value hierarchy for its cash equivalents and marketable securities, which are measured at fair value on a recurring basis at June 30, 2016 and December 31, 2015: Fair Value Measurements at June 30, 2016 Using Level 1 Level 2 Level 3 Total Cash equivalents: Money Market Instruments $ — $ 10,039 $ — $ 10,039 Marketable securities: Certificates of Deposit — 9,980 — 9,980 United States Treasury Notes — 21,791 — 21,791 Total $ — $ 41,810 $ — $ 41,810 Fair Value Measurements at December 31, 2015 Using Level 1 Level 2 Level 3 Total Cash equivalents: Money Market Instruments $ — $ 18,361 $ — $ 18,361 Marketable securities: Certificates of Deposit — 14,887 — 14,887 United States Treasury Notes — 25,047 — 25,047 Total $ — $ 58,295 $ — $ 58,295 The carrying values of accounts payable and accrued expenses approximate their fair value due to the short-term nature of these liabilities.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period. Because the inclusion of common share equivalents in the calculation would be anti-dilutive for all periods presented, diluted net loss per share is the same as basic net loss per share. The following common share equivalents outstanding as of June 30, 2016 and 2015 were excluded from the computation of diluted net loss per share for the three and six months ended June 30, 2016 and 2015 because they had an anti-dilutive impact: June 30, December 31, 2016 2015 Stock options to purchase common stock 2,911,215 2,861,011 Unvested restricted common stock units 34,128 40,953 2,945,343 2,901,964
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2014-15, Presentation of Financial Statements — Going Concern Subtopic 205-40). In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Schedule of Marketable Securities by Security Type	At June 30, 2016, marketable securities by security type consisted of: Gross Gross Estimated Amortized Unrealized Unrealized Fair Cost Gains Losses Value Certificates of Deposit (due within one year) $ 9,980 $ — $ — $ 9,980 United States Treasury Notes (due within one year) 21,785 6 — 21,791 Total $ 31,765 $ 6 $ — $ 31,771 At December 31, 2015, marketable securities by security type consisted of: Gross Gross Estimated Amortized Unrealized Unrealized Fair Cost Gains Losses Value Certificates of Deposit (due within one year) $ 13,709 $ — $ — $ 13,709 Certificates of Deposit (due after one year through two years) 1,178 — — 1,178 United States Treasury Notes (due within one year) 22,596 — (47 ) 22,549 United States Treasury Notes (due after one year through two years) 2,506 — (8 ) 2,498 Total $ 39,989 $ — $ (55 ) $ 39,934
Schedule of Fair Value Measured on Recurring Basis	The following tables present the Company’s fair value hierarchy for its cash equivalents and marketable securities, which are measured at fair value on a recurring basis at June 30, 2016 and December 31, 2015: Fair Value Measurements at June 30, 2016 Using Level 1 Level 2 Level 3 Total Cash equivalents: Money Market Instruments $ — $ 10,039 $ — $ 10,039 Marketable securities: Certificates of Deposit — 9,980 — 9,980 United States Treasury Notes — 21,791 — 21,791 Total $ — $ 41,810 $ — $ 41,810 Fair Value Measurements at December 31, 2015 Using Level 1 Level 2 Level 3 Total Cash equivalents: Money Market Instruments $ — $ 18,361 $ — $ 18,361 Marketable securities: Certificates of Deposit — 14,887 — 14,887 United States Treasury Notes — 25,047 — 25,047 Total $ — $ 58,295 $ — $ 58,295
Schedule of Common Stock Equivalents, Excluded from Computation of Diluted Net Loss per Share	The following common share equivalents outstanding as of June 30, 2016 and 2015 were excluded from the computation of diluted net loss per share for the three and six months ended June 30, 2016 and 2015 because they had an anti-dilutive impact: June 30, December 31, 2016 2015 Stock options to purchase common stock 2,911,215 2,861,011 Unvested restricted common stock units 34,128 40,953 2,945,343 2,901,964

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following: June 30, 2016 December 31, 2015 Accrued research and development expenses $ 4,506 $ 3,188 Accrued payroll and related expenses 934 900 Accrued professional fees 468 699 Accrued other 63 167 $ 5,971 $ 4,954

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock Units	The Company recorded stock-based compensation expense related to stock options and restricted common stock units in the following expense categories of its statements of operations: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Research and development $ 194 $ 140 $ 405 $ 308 General and administrative 798 466 1,609 932 $ 992 $ 606 $ 2,014 $ 1,240

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments Under Noncancelable Office Leases	As of June 30, 2016, future minimum lease payments under noncancelable office leases were as follows: Remainder of 2016 $ 280 2017 839 2018 489 $ 1,608

Nature of the Business and Ba19

Nature of the Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	Jul. 29, 2016	Jun. 30, 2016	Dec. 31, 2015
Accumulated deficit		$ (156,390)	$ (131,438)
Cash and investments		$ 43,927
Subsequent Event [Member]
Percentage of reduction in workforce	60.00%

Summary of Significant Accoun20

Summary of Significant Accounting Policies - Schedule of Marketable Securities by Security Type (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 31,765	$ 39,989
Gross Unrealized Gains	6
Gross Unrealized Losses		(55)
Estimated Fair Value	31,771	39,934
Certificates of Deposit Due within One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	9,980	13,709
Estimated Fair Value	$ 9,980	$ 13,709
Marketable securities, maturity period	1 year	1 year
Certificates of Deposit Due after One Year through Two Years [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 1,178
Estimated Fair Value		$ 1,178
Certificates of Deposit Due after One Year through Two Years [Member] | Minimum [Member]
Schedule of Available-for-sale Securities [Line Items]
Marketable securities, maturity period		1 year
Certificates of Deposit Due after One Year through Two Years [Member] | Maximum [Member]
Schedule of Available-for-sale Securities [Line Items]
Marketable securities, maturity period		2 years
United States Treasury Notes Due Within One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 21,785	$ 22,596
Gross Unrealized Gains	6
Gross Unrealized Losses		(47)
Estimated Fair Value	$ 21,791	$ 22,549
Marketable securities, maturity period	1 year	1 year
United States Treasury Notes Due after One Year through Two Years [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 2,506
Gross Unrealized Losses		(8)
Estimated Fair Value		$ 2,498
United States Treasury Notes Due after One Year through Two Years [Member] | Minimum [Member]
Schedule of Available-for-sale Securities [Line Items]
Marketable securities, maturity period		1 year
United States Treasury Notes Due after One Year through Two Years [Member] | Maximum [Member]
Schedule of Available-for-sale Securities [Line Items]
Marketable securities, maturity period		2 years

Summary of Significant Accoun21

Summary of Significant Accounting Policies - Schedule of Fair Value Measured on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value measurements, cash equivalents and marketable securities	$ 41,810	$ 58,295
Money Market Instruments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value measurements, cash equivalents and marketable securities	10,039	18,361
Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value measurements, cash equivalents and marketable securities	9,980	14,887
United States Treasury Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value measurements, cash equivalents and marketable securities	21,791	25,047
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value measurements, cash equivalents and marketable securities	41,810	58,295
Level 2 [Member] | Money Market Instruments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value measurements, cash equivalents and marketable securities	10,039	18,361
Level 2 [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value measurements, cash equivalents and marketable securities	9,980	14,887
Level 2 [Member] | United States Treasury Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value measurements, cash equivalents and marketable securities	$ 21,791	$ 25,047

Summary of Significant Accoun22

Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents, Excluded from Computation of Diluted Net Loss per Share (Detail) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total options, restricted stock units exercisable or convertible into common stock	2,945,343	2,901,964
Stock Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total options, restricted stock units exercisable or convertible into common stock	2,911,215	2,861,011
Unvested Restricted Common Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total options, restricted stock units exercisable or convertible into common stock	34,128	40,953

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Accrued research and development expenses	$ 4,506	$ 3,188
Accrued payroll and related expenses	934	900
Accrued professional fees	468	699
Accrued other	63	167
Total	$ 5,971	$ 4,954

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Deferred tax assets, gross			$ 51,028,000
Income tax benefits / expense	$ 0	$ 0
Increase in gross deferred tax assets	10,000,000
Unrecognized tax benefits	0		0
Accrued interest or tax penalties	$ 0		$ 0
Income tax earliest examination year	2,012

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail)	Jun. 30, 2016shares
2014 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares available for issuance	1,978,979
2014 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares available for issuance	225,000

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock Units (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 992	$ 606	$ 2,014	$ 1,240
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	194	140	405	308
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 798	$ 466	$ 1,609	$ 932

Commitments and Contingencies27

Commitments and Contingencies (Leases) - Additional Information (Detail) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Jun. 30, 2015	Feb. 28, 2015ft²	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)
Other Commitments [Line Items]
Leases expiration date	Jul. 31, 2018
Exit cost						$ 133
Operating service agreement period						30 days
Rental expense			$ 174	$ 181	$ 347	$ 487
Sublease [Member]
Other Commitments [Line Items]
Area of office space | ft²		15,981
Leases expiration date					Dec. 31, 2016

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Noncancelable Office Leases (Detail) $ in Thousands	Jun. 30, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remainder of 2016	$ 280
2,017	839
2,018	489
Total	$ 1,608

Commitments and Contingencies29

Commitments and Contingencies (Restricted Cash and Letters of Credit) - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Other Commitments [Line Items]
Restricted cash	$ 270	$ 270
Money Market Instruments [Member]
Other Commitments [Line Items]
Restricted cash	200	200
Money Market Instruments [Member] | Letter of Credit [Member]
Other Commitments [Line Items]
Restricted cash	$ 70	$ 70

Commitments and Contingencies30

Commitments and Contingencies (Intellectual Property Licenses) - Additional Information (Detail)	1 Months Ended	6 Months Ended		12 Months Ended
	Jan. 31, 2015USD ($)	Jun. 30, 2016USD ($)AmendmentsMilestone	Jun. 30, 2015USD ($)Milestone	Dec. 31, 2015USD ($)
Other Commitments [Line Items]
Number of milestones achieved | Milestone		0	0
License Agreement [Member] | Johns Hopkins [Member]
Other Commitments [Line Items]
Percentage of non-royalty sub license income	20.00%
Upfront payment			$ 75,000
Potential milestone payments under license agreement	$ 700,000
Milestone payments expensed during period				$ 50,000
Additional liabilities for milestone payments				$ 0
License Agreement [Member] | Johns Hopkins [Member] | Minimum [Member]
Other Commitments [Line Items]
Annual royalty	$ 30,000
Master License Agreement [Member] | UMB [Member]
Other Commitments [Line Items]
Number of amendments | Amendments		4
Annual maintenance fee		$ 10,000
Percentage of non-royalty sub license income		10.00%
Master License Agreement [Member] | UMB [Member] | Minimum [Member]
Other Commitments [Line Items]
Annual royalty		$ 50,000
IND [Member] | Master License Agreement [Member] | UMB [Member] | Upon Filing IND Application For Licensed Product [Member]
Other Commitments [Line Items]
Milestone payment		50,000
IND [Member] | Master License Agreement [Member] | UMB [Member] | Upon FDA Approval [Member]
Other Commitments [Line Items]
Milestone payment		100,000
Investigational Drug Application Non Prostate Disease [Member] | Master License Agreement [Member] | UMB [Member] | Maximum [Member]
Other Commitments [Line Items]
Aggregate milestone payments associated with development of licensed product		$ 150,000

Commitments and Contingencies31

Commitments and Contingencies (Commercial Development Agreement) - Additional Information (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Master Collaboration Agreement [Member] | Qiagen [Member]
Other Commitments [Line Items]
Contingent milestone payment	$ 1,000

401(k) Plan - Additional Inform

401(k) Plan - Additional Information (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Defined Contribution Plan Disclosure [Line Items]
Company contributions to 401 (k) plan	$ 91
Employee's Contributions up to 3% [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer matching contribution, percent	100.00%
Employee's Contributions Between 3% and 5% [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer matching contribution, percent	50.00%
100% of Matching Contribution [Member]
Defined Contribution Plan Disclosure [Line Items]
Percentage of the employee's compensation	3.00%
50% of Matching Contribution [Member]
Defined Contribution Plan Disclosure [Line Items]
Percentage of the employee's compensation	5.00%
50% of Matching Contribution [Member] | Minimum [Member]
Defined Contribution Plan Disclosure [Line Items]
Percentage of the employee's compensation	3.00%

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] $ in Thousands	Jul. 29, 2016USD ($)
Subsequent Event [Line Items]
Percentage of reduction in workforce	60.00%
Third Quarter 2016 [Member]
Subsequent Event [Line Items]
Severance, benefits and related costs	$ 1,300